Drug Trial Radar · NCT07924618
Ocular Changes in Patients Using Tirzepatide or Semaglutide
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Sep 17, 2027
Study completion Sep 17, 2027
Sponsor
- Lead sponsor
- Istanbul UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.
Conditions
- Type 2 Diabetes Mellitus
- Obesity
Interventions
SemaglutideDrug
Semaglutide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.
TirzepatideDrug
Tirzepatide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Retinal Nerve Fiber Layer ThicknessTime frame: Baseline to up to 18 months
- Change in Retinal ThicknessTime frame: Baseline to up to 18 months
- Change in Superficial Retinal Vessel DensityTime frame: Baseline to 18 months
- Change in Deep Retinal Vessel DensityTime frame: Baseline to 18 months
- Change in Foveal Avascular Zone AreaTime frame: Baseline to 18 months
- Change in Choriocapillaris Flow Deficit PercentageTime frame: Baseline to 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istanbul University, Istanbul Faculty of Medicine
Istanbul, Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.